Brief: Merck Publishes Long-Term Efficacy And Safety Data From Phase 3 Defi Trial Of Ogsiveo®

Merck KGaA

21/10/2025 16:12

Oct 21 (Reuters) - MERCK KGAA MRCG.DE:

MERCK KGAA - ANNOUNCES PUBLICATION OF LONG-TERM EFFICACY AND SAFETY DATA FROM THE PHASE 3 DEFI TRIAL OF OGSIVEO® (NIROGACESTAT)

MERCK KGAA - LONG-TERM CONTINUOUS OGSIVEO TREATMENT FOR UP TO 4 YEARS WAS ASSOCIATED WITH FURTHER TUMOR SIZE REDUCTIONS,  INCREASE IN OBJECTIVE RESPONSE RATE

MERCK KGAA - SUSTAINED IMPROVEMENT IN DESMOID TUMOR SYMPTOMS AND CONSISTENT SAFETY PROFILE

Further company coverage: MRCG.DE

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))